Investors & Media

We are driven to develop meaningful therapies for patients while creating value for stockholders.

Investors & Media

Corporate Profile

We are a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS).

Press Releases

Jun 01, 2023

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023

Cyclerion Announces Reverse Stock Split

May 11, 2023

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

view all

Stock Quote

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation July 2022
Top